Drug

Database

Drugs coverage include under development and approved therapies. Drug profile covers exhaustive research, regulatory and market information from global pharm/biotech companies and regulatory websites. Regulatory designations from United States, Europe, Japan, South Korea, Australia, China and United Kingdom regulatory websites. Drug sales and forecast estimates for the major countries. Complex technologies are linked to drugs, companies and deals.

Clinical Trials

Database

Clinical trials, trial sites, investigators and contacts from prominent clinical trial registries. Lot of unstructured data parsed, curated and connected with relevant sponsors, collaborators, interventions, indications, sites and investigators. Conditions are standardized accordingly to match with other data modules.

Executive

Database

Companies, Institutes, Universities and Tech Transfer entities associated with technologies, drugs, contract manufacturing, and clinical research services, and pharma or biotech portfolio investment interest are covered. Platform provides search filters, data exports and alerts on company attributes, financials along with Global Industry Classification System (GICS) and disruptive technologies. Dynamic news, deals coverage and key people contacts by department.

Contract Services

Database

Contract services database covers manufacturing, clinical trials and packaging companies with their capabilities. Covers drugs, contacts, news, agreements, certifications and warnings issued by manufacturing facility and clinical site.

Generics and Drug Master File (DMF)

Database

Covers generic drugs from developed and developing market countries with their reference drugs. Sales & marketing and market strategy teams can make most use of the data as it gives broader view on generic market by country. Active Drug Master Files (DMF) data by generic name and company from United States, EU, Japan and South Korea combined with generic approval data. Companies with only DMF approvals are the right target companies to make service agreements for generic companies.

Industry Trends, Diseases & Countries

Database

Instant data view on global pipeline and approved drugs, associated companies, clinical trials, trial sites, investigators, drug price, drug sales and regulatory information for the required data set. Data visualization and analytics based on the content helps you with ready-to-use exports and analytics. Dynamic updates and new additions as per your subscribed content saves time and money.

Disease Landscape

Database

Database covers major unmet need and rare indications by incidence, prevalence, disease characteristics, and market size for more than 40+ countries. Customized insights on current treatments, promising pipeline drugs, active companies/institutes/universities and active trial sponsors/collaborators. Strategic data representation with drug sales and forecast, patent landscape, review designations, strategic deals and licensing opportunity data.

Intelligence Tool

Database

Company competitive intelligence tool provides similar companies by Headquarters, Disease Area, Nature of Molecule, Pipeline/Approved stages and Business Type. Provides ready-to-use templates by company with basic details, financials, key people, drug sales and performance Metrix. Clinical Trial Planner tool provides subjects/sites/investigators availability by Drug Indication, Phase and Nature of Molecule, and Enrollment Size.

Databases

Comprehensive coverage on biopharmaceutical companies, universities, drugs, clinical trials, disease epidemiology, patent expiry, drug sales and projections, regulatory, generics, drug master files and manufacturing attributes. Simple search navigations, customizable display and exports meets different clientele requirements. Pre-defined analytics with ready-to-use exports, and alerts functionality brings you requires data daily basis.

Intelligence Platforms

Company competitive intelligence tool provides similar companies by Headquarters, Disease Area, Nature of Molecule, Pipeline/Approved stages and Business Type. Provides ready-to-use templates by company with basic details, financials, key people, drug sales and performance Metrix.
Clinical Trial Planner tool provides subjects/sites/investigators availability by Drug Indication, Phase and Nature of Molecule, and Enrollment Size.

Industry Trends

Instant data view on global pipeline and approved drugs, associated companies, clinical trials, trial sites, investigators, drug price, drug sales and regulatory information for the required data set. Data visualization and analytics based on the content helps you with ready-to-use exports and analytics. Dynamic updates and new additions as per your subscribed content saves time and money.


Disease Landscape

Database covers major unmet need and rare indications by incidence, prevalence, disease characteristics, and market size for more than 40+ countries. Customized insights on current treatments, promising pipeline drugs, active companies/institutes/universities and active trial sponsors/collaborators. Strategic data representation with drug sales and forecast, patent landscape, review designations, strategic deals and licensing opportunity data.

Monthly Newsletter

Doloxe’s newsletter covers advanced therapies companies financing, licensing deals, merger & acquisitions, drug development, regulatory updates, key people hiring and new companies. These will act as business leads for service provides and investor companies.






About Us

Precise Understanding

About the Market

Doloxe offers centralized data repository that caters data intelligence, trends and insights as a service to help organization make informed decisions.

INNOVATION

Our data experts and softwares curate all your requirments into actionable insights.

DATA AUTHENTICITY

Curate data from company websites, press newswires, financial statements and reports. Each deliverable include data specific source types for your reference.

DELIVERY

Single platform for pharmaceutical industry data research, market and projections.

CONSULTING

Consulting services based on your goals and return on investment (ROI) optimised strategies on any selected industry trend and disease landscape report.

REPORTING

Data analytics from multiple platforms helps you ready-to-use presentation templates for the strategy meetings and key analysis.

COMPETITIVENESS

Know and inspect new and enhancements from our competitors and add value-driven offerings to support you with integrated platform approach.

Customer Centric Approach

Doloxe foresee customer success through their products and services along with other biopharma players. We get into the customer strategy, align with their offerings and come up with better solutions. Our technologies ensure data solutions are comprehensive and making an insightful offering. Each insight derives from the depth and breadth of the drug development cycle, includes technology, drug phase, molecule structure, route of administration, disease analysis, multiple entities such as originator, licensor, licensee, technology partner, CRO, CDMO/CMO, clinical trial location, investigator, pivotal trial, patents, future events, drug price and reimbursement.
Customer service is our opportunity to fill gap within the biopharmaceutical industry supply chain. We strive to create value addition to each industry player requirements and make more customer success stories.
Our leadership, scientific and technology team strives for continuous improvements in terms of client friendly data technologies, latest scientific innovations and access to the right analyst.
Query management team ensures with relevant reply within promised turnaround time.

Our support staff will respond to your customized requirements and queries as soon as possible.

Ask Analyst

Our customer success team work alongside with your account manager to support you on all modules and intelligence platforms. Our objective is to make use of our modules and benefit with informed decisions.

Contact Us

We have 24/5 support across all regions, please shoot us an email if you have access issues or have any urgent requirements

Client Support

We keep you informed, profound and favorable decisions to encompass the advantages of upcoming trends, progressions, estimations, and opportunities through our precise understanding of the market.

How can we help?

Submit

Latest News

Linerixibat shows positive Phase III results in cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC)

Primary endpoint met with a statistically significant improvement in itch over 24 weeks compared with placebo
Linerixibat has the potential to be the first global therapy indicated to treat itch...

Read more..
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints

Investigational subcutaneous pembrolizumab and berahyaluronidase alfa, in combination with chemotherapy, demonstrates noninferior pharmacokinetics compared to intravenous KEYTRUDA in combination with ...

Read more..
Tagrisso recommended for approval in the EU by CHMP for patients with unresectable EGFR-mutated lung cancer

Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years

AstraZeneca’s Tagrisso (osimertinib) has bee...

Read more..
AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer

ELAHERE is the first and only novel therapy approved in the European Union specifically for patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer
ELAHERE represen...

Read more..
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Opinion based on results from the Phase 3 CheckMate -8HW trial, in which the dual immunotherapy combination of Opdivo and Yervoy demonstrated statistically significant and clinically meaningful improv...

Read more..